Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	$16.86	+19.78%	63,650
05/11/26	$14.08	-8.20%	17,861
04/11/26	$15.33	+6.48%	26,085
03/11/26	$14.40	-5.51%	8,822
02/11/26	$15.24	-2.35%	15,077

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.86USD

Average target price

600.00USD

Spread / Average Target

+3,458.72%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Jasper Therapeutics A

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Jasper Therapeutics A

Company calendar

Delayed Nasdaq 01:00:00 07/11/2026 +04			5-day change	1st Jan Change
16.86 ^USD	+19.78%		+8.04%	-69.29%

10-15	Jasper Therapeutics, Inc. Completes Enrollment of Iga Nephropathy Cohort of Phase 2 Basket Study Evaluating Vensobafusp Alfa	CI
09-29	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI

Market Cap	18.7M 16.77M 15.33M 13.99M 26.36M 1.76B 27.19M 185M 73.67M 938M 70.19M 68.69M 2.96B	P/E 2026 *	-	P/E 2027 *	-5.62x
Enterprise Value	18.7M 16.77M 15.33M 13.99M 26.36M 1.76B 27.19M 185M 73.67M 938M 70.19M 68.69M 2.96B	EV / Sales 2026 *	3.12x	EV / Sales 2027 *	-
Free-Float	97.45%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	JSPR	Delayed
CBOE	JSPR	Real-time

10-15	Jasper Therapeutics, Inc. Completes Enrollment of Iga Nephropathy Cohort of Phase 2 Basket Study Evaluating Vensobafusp Alfa	CI
09-29	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI
09-29	Jasper Therapeutics, Inc. Announces Management Changes, Effective October 9, 2026	CI
09-18	Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to NASDAQ Composite Index	CI
09-15	Jasper Therapeutics, Inc. Appoints Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President	CI
08-14	Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
08-05	Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors	CI
07-17	Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026	CI
07-17	Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall	MT
07-16	Kira Pharmaceuticals acquired Jasper Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.	CI
07-16	Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding	CI
06-02	Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value	CI

Jasper Therapeutics A Stock

Stocks

JSPR

US4718712023

Biotechnology & Medical Research

Valuation: Jasper Therapeutics A

Chart: Jasper Therapeutics A

Latest news: Jasper Therapeutics A

Last Transcript: Jasper Therapeutics A

Analysts' recommendations: Jasper Therapeutics A

Press Releases: Jasper Therapeutics A

News in other languages: Jasper Therapeutics A

Quotes and Performance

Price Extremes

Managers and Directors: Jasper Therapeutics A

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
05-15	RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk	MT
05-15	TD Cowen Downgrades Jasper Therapeutics to Hold From Buy	MT
03-23	UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25	MT
11-11	RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk	MT

10-07	Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants	AQ
09-16	Jasper Therapeutics Announces Key Regulatory and Clinical Appointments	AQ
09-09	Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-17	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
08-14	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ

19/09/25	USA-Les valeurs à suivre à Wall Street (actualisé)
16/11/21	MÄRKTE USA/Kaum verändert - Zwischen China-Hoffnung und Zinssorgen
15/11/21	MÄRKTE USA/Wall Street dreht leicht ins Minus
15/11/21	MÄRKTE USA/Wall Street mit Vorschusslorbeeren für Biden-Xi-Gipfel
15/11/21	MÄRKTE USA/Wall Street vor Biden-Xi-Gipfel leicht optimistisch

1 day	+19.78%
1 week	+8.04%
Current month	+8.04%
1 month	+0.36%
3 months	-20.79%
6 months	-39.33%
Current year	-69.29%

1 week	12.76	17
1 month	12.76	17.31
Current year	9.45	62.1
1 year	9.45	72.6
3 years	9.45	930.3
5 years	9.45	3,207
10 years	9.45	5,664.01

Manager	Title	Age	Since
Jeet Mahal CEO	Chief Executive Officer	54	06/01/2026
Matthew Ros COO	Chief Operating Officer	59	16/07/2026
Daniel Adelman CTO	Chief Tech/Sci/R&D Officer	68	23/03/2023

Director	Title	Age	Since
Jeet Mahal BRD	Director/Board Member	54	06/01/2026
Judith Shizuru BRD	Director/Board Member	70	04/09/2021
Kurt von Emster BRD	Director/Board Member	59	24/09/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/07/26	Judith Shizuru	Free	Founder	7,500	0.0267%
31/07/26	Patrick Crutcher	Free	Director	7,500	0.0267%
31/07/26	Thomas Wiggans	Free	Chairman	7,500	0.0267%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JASPER THERAPEUTICS A	+19.78%	+8.04%	-68.43%	-92.99%	18.7M
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+62.02%	66.7B
ARGENX SE	+2.97%	+7.14%	+12.72%	+82.41%	56.88B
LONZA GROUP AG	-0.26%	+2.04%	+23.86%	+94.99%	56.53B
BEONE MEDICINES AG	+1.19%	+9.89%	+27.19%	+103.27%	46.49B
IQVIA HOLDINGS INC.	+0.88%	+1.68%	+29.16%	+36.08%	44.8B
REVOLUTION MEDICINES, INC.	+0.51%	+0.51%	+215.16%	+807.84%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+53.61%	35.35B
GENMAB A/S	+1.83%	-2.14%	+92.96%	+64.87%	33.29B
INSMED INCORPORATED	-1.12%	+1.62%	-39.69%	+381.71%	25.1B
Average	+1.82%	+3.19%	+37.61%	+159.38%	40.67B
Weighted average by Cap.	-0.28%	+3.07%	+50.03%	+166.79%

	2026 *	2027 *
Net sales	6M 5.38M 4.92M 4.49M 8.46M 564M 8.73M 59.28M 23.64M 301M 22.52M 22.04M 950M	-
Net income	-	-63.86 -57.27 -52.34 -47.78 -90.02 -6K -92.86 -630.92 -251.58 -3.2K -239.69 -234.55 -10.11K
Net Debt	-	-